2-(5-氯噻吩-2-基)乙胺盐酸盐 | 548772-42-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(5-氯噻吩-2-基)乙胺盐酸盐
• 英文名称: 2-(5-chlorothiophen-2-yl)ethylamine hydrochloride
• 英文别名: 2-(5-chlorothiophen-2-yl)ethan-1-amine hydrochloride；2-(5-chloro-[2]thienyl)-ethylamine; hydrochloride；2-(5-Chlor-[2]thienyl)-aethylamin; Hydrochlorid；2-(5-Chlorothiophen-2-YL)ethanamine hydrochloride；2-(5-chlorothiophen-2-yl)ethanamine;hydrochloride
• CAS: 548772-42-5
• 化学式: C₆H₈ClNS*ClH
• mdl: MFCD08234649
• 分子量: 198.116
• InChiKey: POJXZNWFJAMOSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.07
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  54.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-(5-氯噻吩-2-基)乙胺盐酸盐 、 imidazole-1-carbothionic acid (5-bromopyridin-2-yl)amide 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 N-[2-(5-chlorothiophen-2-yl)ethyl]-N'-(5-bromo-2-pyridyl)thiourea
  参考文献：
  名称：

  Regiospecific Synthesis of 5‐Halo‐substituted Thiophene Pyridyl Thiourea Compounds as Non‐nucleoside Inhibitors of HIV‐1 Reverse Transcriptase

  摘要：

  The regiospecific synthesis of 5-halothiophenethylamines and halosubstituted phenylethyl thioureas was accomplished with an overall yield of 45 - 60%. Condensation of t-boc protected 2-thiophenethylamine with N-halo succinamide in dimethylformamide furnished the desired halo-substituted thiophenethylamines. These thiophenethyl amines were further converted into biologically active thiourea compounds using thiocarbonyldiimidazole chemistry. Several of the halo-substituted thiophene pyridyl thiourea compounds inhibited HIV-1 reverse transcriptase (RT) at nanomolar concentrations.

  DOI：

  10.1081/scc-120039499
• 作为产物：
  描述：

  噻吩乙胺 在 磺酰氯 、 溶剂黄146 作用下， 以 乙醚 为溶剂， 以60%的产率得到2-(5-氯噻吩-2-基)乙胺盐酸盐
  参考文献：
  名称：

  Mono-Chlorination of Electron-Rich Arylalkyl- and Heteroarylalkyl-amines and Amino Acids Using Sulfuryl Chloride

  摘要：

  硫酰氯用于对富电子的芳基烷基和杂芳基烷基胺及氨基酸进行单氯化，采用温和高效的一锅法转化，可直接纯化。对胺类的保护不是必需的，且手性氨基酸的消旋化程度较低。

  DOI：

  10.1055/s-2003-37362

文献信息

• SPIRO COMPOUND AND USE THEREOF
  申请人：Taniguchi Takahiko

  公开号：US20100069351A1

  公开（公告）日：2010-03-18

  The present invention aims to provide a novel SCD inhibitor. The present invention relate to SCD inhibitor comprising A compound represented by the formula (I) wherein R is an optionally substituted cyclic group or an optionally substituted carbamoyl group, provided that R is not an optionally substituted 7-pyrido[2,3-d]pyrimidyl group; ring A is an optionally further substituted pyridazine ring; R 1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 13 and R 14 are each independently a hydrogen atom or a substituent, or R 1 and R 11 in combination, R 2 and R 12 in combination, R 3 and R 13 in combination, or R 4 and R 14 in combination optionally form an oxo group, or R 2 and R 4 in combination optionally form a bond or an alkylene cross-linkage; m and n are each independently an integer of 0 to 2; ring B is an optionally substituted ring, provided that the two atoms constituting ring B, which are adjacent to the spiro carbon atom, are not oxygen atoms at the same time, or a salt thereof, or a prodrug thereof.

  本发明旨在提供一种新型SCD抑制剂。本发明涉及一种包括下式（I）所表示的化合物的SCD抑制剂：其中R是一个可选择取代的环基或可选择取代的氨甲酰基，但R不是一个可选择取代的7-吡啶并[2,3-d]嘧啶基团；环A是一个可选择进一步取代的吡啶并嘧啶环；R1、R2、R3、R4、R11、R12、R13和R14分别独立地是氢原子或取代基，或R1和R11的组合体，R2和R12的组合体，R3和R13的组合体，或R4和R14的组合体可选择形成氧基，或R2和R4的组合体可选择形成键或烷基交联；m和n分别独立地是0到2的整数；环B是一个可选择取代的环，但构成环B的两个与螺碳原子相邻的原子不同时为氧原子，或其盐，或其前药。
• Novel Compounds 569
  申请人：Connolly Stephen

  公开号：US20080207698A1

  公开（公告）日：2008-08-28

  The present invention provides compounds of formula (I) wherein R a , R b , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 29 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）化合物，其中Ra，Rb，R1，R2，R3，R4，R5，R6和R29如规范中所定义，以及它们的制备方法，包含它们的药物组合物和它们在治疗中的使用。
• 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY
  申请人：Connolly Stephen

  公开号：US20100022491A1

  公开（公告）日：2010-01-28

  The present invention provides compounds of formula (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein Ra, Rb, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 29 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式(I)的化合物（这里应插入一个化学式 - 请参阅随附的纸质副本），其中Ra，Rb，R1，R2，R3，R4，R5，R6和R29如规范中定义的那样，它们的制备过程，包含它们的制药组合物以及它们在治疗中的使用。
• Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action
  作者：Michael Lückmann、Aslihan Shenol、Tinne A. D. Nissen、Jacob E. Petersen、David Kouvchinov、Thue W. Schwartz、Thomas M. Frimurer

  DOI：10.1021/acsmedchemlett.2c00160

  日期：2022.12.8
• 4-HYDR0XY-2-0X0-2, 3 -DIHYDRO- 1, 3-BENZOTHIAZOL- 7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP2121642A1

  公开（公告）日：2009-11-25